Tags

Type your tag names separated by a space and hit enter

Insulin lispro: a fast-acting insulin analog.
Am Fam Physician. 1998 Jan 15; 57(2):279-86, 289-92.AF

Abstract

Research has established the importance of maintaining blood glucose levels near normal in patients with type 1 (insulin-dependent) diabetes mellitus. Short-acting insulin analogs are designed to overcome the limitations of regular short-acting insulins. Compared with regular human insulin, the analog insulin lispro offers faster subcutaneous absorption, an earlier and greater insulin peak and a more rapid postpeak decrease. Insulin lispro begins to exert its effects within 15 minutes of subcutaneous administration, and peak levels occur 30 to 90 minutes after administration. Duration of activity is less than five hours. Rates of insulin allergy, lipodystrophy, hypoglycemia and abnormal laboratory test results are essentially the same in patients using insulin lispro and in those using regular human insulin.

Links

FREE Publisher Full Text

Authors+Show Affiliations

Noble SL
University of Mississippi Medical Center, Jackson, USA.
Johnston E
No affiliation info available
Walton B
No affiliation info available

MeSH

Blood GlucoseDiabetes MellitusHumansHypoglycemiaHypoglycemic AgentsInsulinInsulin LisproPatient Education as Topic

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

9456992

Citation

Noble, S L., et al. "Insulin Lispro: a Fast-acting Insulin Analog." American Family Physician, vol. 57, no. 2, 1998, pp. 279-86, 289-92.
Noble SL, Johnston E, Walton B. Insulin lispro: a fast-acting insulin analog. Am Fam Physician. 1998;57(2):279-86, 289-92.
Noble, S. L., Johnston, E., & Walton, B. (1998). Insulin lispro: a fast-acting insulin analog. American Family Physician, 57(2), 279-86, 289-92.
Noble SL, Johnston E, Walton B. Insulin Lispro: a Fast-acting Insulin Analog. Am Fam Physician. 1998 Jan 15;57(2):279-86, 289-92. PubMed PMID: 9456992.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Insulin lispro: a fast-acting insulin analog. AU - Noble,S L, AU - Johnston,E, AU - Walton,B, PY - 1998/2/11/pubmed PY - 1998/2/11/medline PY - 1998/2/11/entrez SP - 279-86, 289-92 JF - American family physician JO - Am Fam Physician VL - 57 IS - 2 N2 - Research has established the importance of maintaining blood glucose levels near normal in patients with type 1 (insulin-dependent) diabetes mellitus. Short-acting insulin analogs are designed to overcome the limitations of regular short-acting insulins. Compared with regular human insulin, the analog insulin lispro offers faster subcutaneous absorption, an earlier and greater insulin peak and a more rapid postpeak decrease. Insulin lispro begins to exert its effects within 15 minutes of subcutaneous administration, and peak levels occur 30 to 90 minutes after administration. Duration of activity is less than five hours. Rates of insulin allergy, lipodystrophy, hypoglycemia and abnormal laboratory test results are essentially the same in patients using insulin lispro and in those using regular human insulin. SN - 0002-838X UR - https://www.unboundmedicine.com/medline/citation/9456992/Insulin_lispro:_a_fast_acting_insulin_analog_ L2 - https://www.aafp.org/link_out?pmid=9456992 DB - PRIME DP - Unbound Medicine ER -